Boston Scientific Acquires Penumbra for Over $14 Billion

Boston Scientific Corp. has announced its agreement to acquire medical device manufacturer Penumbra Inc. in a deal valued at over $14 billion. This strategic acquisition aims to enhance Boston Scientific’s portfolio in the cardiovascular treatment sector. The company will offer $374 per share in cash and stock for Penumbra, a premium of approximately 19 percent over Penumbra’s closing price on March 13, 2024.

Under the terms of the agreement, Penumbra shareholders can choose to receive either $374 in cash or 3.8721 shares of Boston Scientific common stock. Boston Scientific has stated that the deal, which carries an equity value of about $14.6 billion, is anticipated to close within the year. This acquisition reflects Boston Scientific’s commitment to expanding its capabilities in rapidly growing medical categories.

As the news of the acquisition broke, shares of Penumbra surged by 14 percent in early trading on the New York Stock Exchange, adding to a remarkable 24 percent increase over the previous year. In contrast, shares of Boston Scientific experienced a premarket decline of 3.9 percent amidst market reactions.

Based in California, Penumbra specializes in innovative products that target conditions such as strokes and pulmonary embolisms, addressing critical medical needs. The company reported a significant sales increase of over 17 percent in the last financial year, showcasing its growth potential and market relevance.

Boston Scientific emphasized that this acquisition opens avenues for entering high-growth market segments within the medical device industry. The integration of Penumbra’s technology and expertise is expected to bolster Boston Scientific’s offerings, particularly in the realm of cardiovascular health, which is increasingly important in today’s healthcare landscape.

This acquisition marks a significant milestone in Boston Scientific’s strategic expansion efforts, positioning the company to better serve patients and healthcare providers with enhanced treatment options in the cardiovascular arena.